Therasense Current Valuation vs. Total Debt

THER Stock  USD 0.0001  0.00  0.00%   
Based on the measurements of profitability obtained from Therasense's financial statements, Therasense may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Therasense's ability to earn profits and add value for shareholders.
For Therasense profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Therasense to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Therasense utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Therasense's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Therasense over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
Please note, there is a significant difference between Therasense's value and its price as these two are different measures arrived at by different means. Investors typically determine if Therasense is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Therasense's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Therasense Total Debt vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Therasense's current stock value. Our valuation model uses many indicators to compare Therasense value to that of its competitors to determine the firm's financial worth.
Therasense is currently regarded number one company in current valuation category among its peers. It is rated second in total debt category among its peers making up about  0.11  of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for Therasense is roughly  9.41 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Therasense's earnings, one of the primary drivers of an investment's value.

Therasense Current Valuation vs. Competition

Therasense is currently regarded number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is at this time estimated at about 402.42 Million. Therasense holds roughly 27.3 Million in current valuation claiming about 7% of stocks in Biotechnology industry.

Therasense Total Debt vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Therasense

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
27.3 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.

Therasense

Total Debt

 = 

Bonds

+

Notes

 = 
2.9 M
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.

Therasense Total Debt vs Competition

Therasense is rated second in total debt category among its peers. Total debt of Biotechnology industry is at this time estimated at about 115.64 Million. Therasense holds roughly 2.9 Million in total debt claiming about 2.51% of stocks in Biotechnology industry.
Total debt  Valuation  Revenue  Workforce  Capitalization

Therasense Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Therasense, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Therasense will eventually generate negative long term returns. The profitability progress is the general direction of Therasense's change in net profit over the period of time. It can combine multiple indicators of Therasense, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. Theralink Technologies operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.

Therasense Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Therasense. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Therasense position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Therasense's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Therasense without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Use Investing Themes to Complement your Therasense position

In addition to having Therasense in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Market Neutral Funds Thematic Idea Now

Market Neutral Funds
Market Neutral Funds Theme
Funds or Etfs that invest in both long and short positions of different entities to enhance returns from broad market movements over time. The Market Neutral Funds theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Market Neutral Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Therasense Pink Sheet Analysis

When running Therasense's price analysis, check to measure Therasense's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Therasense is operating at the current time. Most of Therasense's value examination focuses on studying past and present price action to predict the probability of Therasense's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Therasense's price. Additionally, you may evaluate how the addition of Therasense to your portfolios can decrease your overall portfolio volatility.